eyenovia-logo 3
  • myopia
  • mydriasis
  • Glaucoma
  • dry eye

Prevention of Myopia Progression


MicroPineTM is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with significant eye damage including retinal detachment, choroidal and retinal atrophy and choroidal neovascularization, all of which can lead to permanent vision loss. In the US alone, there are more than 5 million children with myopia and many times more that number in Asia. Eyenovia’s delivery technology is particularly well-suited for this application, allowing children to easily self-administer medication while minimizing dose-related side effects and, through our smart technology, providing dosing reminders to help ensure the best possible outcome from treatment.


Myopia Progression

Unlike nearsightedness which we correct with glasses and laser eye surgery, myopic progression is a vision-threatening, back-of-the-eye disease characterized by uncontrolled stretching of the sclera and the retina which can lead to retinal detachment, atrophy and vision loss.



Pharmacologic Mydriasis

MicroStatTM is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (eye dilation). Almost everyone who has had an eye examination has been treated with these drugs – there are more than 80 million topical applications performed every year in the US. Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, by reducing the number of doses in half and minimizing dose-related side effects (including the need to wipe away excess drug that may fall out of the eye).


US 80M eye exams

Chronic Angle Closure Glaucoma

MicroProstTM is our proprietary prostaglandin microdose formulation and candidate for the first-line treatment of chronic angle closure glaucoma (CACG). Currently there are no prostaglandin approved by the FDA for CACG, which accounts for 10% of all glaucoma diagnoses in the US and up to half of all in China.

CACG is a chronic disease in which most of the 580,000+ patients in the US will require life-long therapy to lower their intraocular pressure and reduce the risk of disease progression.


Chronic Angle Closure Glaucoma

Similar to open-angle glaucoma, angle-closure glaucoma is characterized by increased intraocular pressure leading to optic nerve damage and vision loss. Unlike Open-Angle Glaucoma, it is a clinically different disease entity with a distinct anatomy, pathophysiology and treatment paradigm.


MicroTears for Dry Eye: 

MicroTearsTM is our highly differentiated microdrop ocular surface tear replenishment for the $2 billion US dry eye market. Dry eye syndrome (“DES”) is a common condition with more than 20 million suffers in the US alone. Twenty-five percent of patients visiting an eye care doctor report symptoms of dry eye. Our technology may help these patients treat their condition more effectively and efficiently by addressing the difficulties many patients have in putting in eye drops as well as minimizing waste associated with “flooding” the eye.